| Quantity: | |
|---|---|
Product: Dysport (abobotulinumtoxinA).
Strength: 500 units (U) in a single-use vial.
Form: A powder that is reconstituted (mixed) with sterile saline before injection.
Dysport is a prescription-only injectable medication containing abobotulinumtoxinA, a purified form of botulinum toxin type A. Manufactured by Ipsen Biopharmaceuticals, it is clinically proven to temporarily relax targeted muscles by blocking nerve signals. Available in 300-unit and 500-unit vials as a lyophilized powder for reconstitution, Dysport is widely used in both aesthetic and therapeutic settings across more than 80 countries. It has been approved by the U.S. FDA and other global regulatory bodies for specific indications, with over 15 years of clinical evidence supporting its safety and efficacy.
Cosmetic: Temporarily improves moderate to severe glabellar lines (frown lines between the eyebrows) in adults under 65 years old.
Therapeutic: Treats cervical dystonia in adults to reduce abnormal head posture and associated neck pain.
Spasticity Management: Addresses focal spasticity in upper and lower limbs for patients aged 2 years and older, including those with neurological conditions such as cerebral palsy or stroke-related spasticity.
Dysport must be administered by a qualified healthcare professional via intramuscular or subcutaneous injection. The powder is reconstituted with sterile saline prior to use. Dosage and injection sites are customized based on the patient’s condition, muscle mass, and treatment goals. For cosmetic use, typical injections target the corrugator and procerus muscles. For therapeutic applications, dosing is calculated per unit of body weight or affected muscle group. Effects typically begin within 2–3 days and last approximately 3–4 months. Patients should avoid rubbing the treated area for 24 hours post-injection and follow up with their provider for optimal results and monitoring. Storage requires refrigeration at 2°C to 8°C.
